Lavendustin A, formerly known as RG 14355, is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 11 nM).

Almonertinib hydrochloride (HS10296) is a novel, potent, orally bioavailable, 3rd-generation irreversible inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity.

Olafertinib, formerly known as CK-101 and Olafertinib, is a potent and orally bioavailable EGFR mutant-specific inhibitor.

EGFR inhibitor is a novel and potent EGFR inhibitor which directly depolymerizes microtubules and is used as a chemical probe to investigate both the EGFR pathway and microtubule dynamics.

Allitinib tosylate (formerly AST-1306; AST1306; AST 1306), the tosylate of Allitinib, is a selective and covalent/irreversible inhibitor of EGFR and ErbB2 with potential anticancer activity.

AZD9291-DA (also known as Mutated EGFR-IN-1 or Osimertinib analog) is a des acryl analogue of AZD9291, which is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.

Gefitinib hydrochloride, the HCl salt of Gefitinib (formerly also known as ZD1839 or trade name: Iressa), is a potent and orally-bioavailable EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

AZ7550 (AZ-7550; AZ 7550) is an active metabolite of AZD-9291 (Osimertinib, a marketed anticancer drug) which inhibits the activity of IGF1R with an IC50 of 1.6 μM.

TQB-3804 (TQB3804; EGFR-IN-7; compound 34) is a 4th-generation, oralli bioactive and selective EGFR kinase inhibitor (EGFR-TKI, developed in China and disclosed in patent WO2019015655A1) with potential anticancer activity.

EAI045 (EAI-045) is a 4th generation selective & allosteric EGFR inhibitor overcoming T790M and C797S resistance.